Moraxellaceae

Entasis Therapeutics Highlights Multiple Data Presentations at Virtual ID Week

Retrieved on:

Wednesday, October 14, 2020

Medical specialties, Bacteriology, Microbiology, Bacterial diseases, Moraxellaceae, Gram-negative bacteria, Pathogenic bacteria, Acinetobacter baumannii, Acinetobacter, Multidrug-resistant Gram-negative bacteria, Pseudomonas infection, Drug resistance

Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria.

Key Points:

Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria.
Entasis pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae infections), ETX0282CPDP (targeting Enterobacteriaceae infections) and ETX0462 (targeting Pseudomonas infections).
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
These forward-looking statements are based on Entasis expectations and assumptions as of the date of this press release.

OpGen Announces Award of German Government Grant Funding to its Subsidiary Curetis and Collaborators

Retrieved on:

Wednesday, September 30, 2020

Medical specialties, Branches of biology, Clinical medicine, Pathogenic bacteria, Healthcare-associated infections, Carbapenem, Moraxellaceae, Pseudomonadales, Drug resistance, Efflux, Acinetobacter, Porin

Furthermore, the project aims to address resistance mechanisms in difficult-to-treat Gram-negative pathogens such as Enterobacteria, Pseudomonas and Acinetobacter.

Key Points:

Furthermore, the project aims to address resistance mechanisms in difficult-to-treat Gram-negative pathogens such as Enterobacteria, Pseudomonas and Acinetobacter.
Curetis role during the collaborative research project is to provide research on innovative detection methods for carbapenem resistance based on porin loss and efflux pump overexpression.
Resistance is often conferred by mechanisms such as porin loss or efflux pump overexpression, not adequately covered by current diagnostics.
This press release includes statements regarding the receipt of a grant from the German government by Curetis GmbH.

Venatorx Pharmaceuticals Awarded up to $44.2 Million to Advance Novel Inhibitors of Penicillin Binding Proteins targeting WHO Critical Priority Pathogen

Retrieved on:

Monday, July 27, 2020

75N93020C00016, the total estimated cost of the base period for this contract is approximately $3.2 million.

Key Points:

75N93020C00016, the total estimated cost of the base period for this contract is approximately $3.2 million.
Venatorx has the potential to receive funding of up to $44.2 million, if all project milestones are met.
A. baumannii is ranked as a Priority 1: Critical carbapenem resistant pathogen on the World Health Organizations list of bacteria for which new antibiotics are urgently needed.
Venatorx is a private pharmaceutical company focused on the discovery and development of novel anti-infectives to treat multi-drug-resistant bacterial infections and hard-to-treat viral infections.

Zai Lab Announces First Chinese Patient Dosed in the Global Phase 3 ATTACK Trial of Sulbactam-Durlobactam for Patients with Carbapenem-Resistant Acinetobacter Infections

Retrieved on:

Monday, May 18, 2020

Infectious diseases, Moraxellaceae, Bacteria, Microbiology, Healthcare-associated infections, Gram-negative bacteria, Acinetobacter baumannii, Pathogenic bacteria, Acinetobacter, Carbapenem

With over 200,000 occurrences estimated each year, China ranks among the countries with the highest incidence of A. baumannii infections in the world.

Key Points:

With over 200,000 occurrences estimated each year, China ranks among the countries with the highest incidence of A. baumannii infections in the world.
ATTACK is a global, two-part Phase 3 registrational trial enrolling approximately 300 patients with pneumonia and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii.
A Phase 2 trial and several Phase 1 trials of SUL-DUR have recently been completed with positive results for pharmacokinetics and safety/tolerability.
These forward-looking statements should not be relied upon as representing Zai Labs views as of any date subsequent to the date of this press release.

Antabio Receives QIDP Designation From the U.S. FDA for the Development of MEM-ANT3310, a Novel Broad-Spectrum Combination Therapy Targeting WHO's Priority Pathogens

Retrieved on:

Wednesday, May 6, 2020

Drugs, Health, Medicine, Carbapenem antibiotics, Moraxellaceae, Bacterial diseases, Gram-negative bacteria, Meropenem, RTT, Acinetobacter baumannii, β-Lactamase inhibitor, Beta-lactamase

ANT3310 potentiates meropenem activity against CRAB in murine infection models and restores meropenem susceptibility in 95% of A. baumannii clinical isolates.

Key Points:

ANT3310 potentiates meropenem activity against CRAB in murine infection models and restores meropenem susceptibility in 95% of A. baumannii clinical isolates.
This is Antabio's second program to receive QIDP status, following QIDP designation of its Metallo Beta-Lactamase Inhibitor ANT2681 for cUTI awarded in June 2019.
Antabio is a private biopharmaceutical company developing novel antibacterial resistance-breakers to treat drug resistant infections in areas of highest unmet medical need.
Antabio is developing a portfolio of three programs which address WHO critical priority pathogens, and which are eligible for QIDP and streamlined development:
SBLi Program.

Antabio Receives QIDP Designation From the U.S. FDA for the Development of MEM-ANT3310, a Novel Broad-Spectrum Combination Therapy Targeting WHO's Priority Pathogens

Retrieved on:

Wednesday, May 6, 2020

Drugs, Health, Medicine, Carbapenem antibiotics, Moraxellaceae, Bacterial diseases, Gram-negative bacteria, Meropenem, RTT, Acinetobacter baumannii, β-Lactamase inhibitor, Beta-lactamase

ANT3310 potentiates meropenem activity against CRAB in murine infection models and restores meropenem susceptibility in 95% of A. baumannii clinical isolates.

Key Points:

ANT3310 potentiates meropenem activity against CRAB in murine infection models and restores meropenem susceptibility in 95% of A. baumannii clinical isolates.
This is Antabio's second program to receive QIDP status, following QIDP designation of its Metallo Beta-Lactamase Inhibitor ANT2681 for cUTI awarded in June 2019.
Antabio is a private biopharmaceutical company developing novel antibacterial resistance-breakers to treat drug resistant infections in areas of highest unmet medical need.
Antabio is developing a portfolio of three programs which address WHO critical priority pathogens, and which are eligible for QIDP and streamlined development:
SBLi Program.

KBP Biosciences Announces Publication of Potent In Vitro Activity of KBP-7072 Against Acinetobacter baumannii

Retrieved on:

Tuesday, April 28, 2020

Medicine, Medical specialties, Infectious diseases, Moraxellaceae, Gram-negative bacteria, Healthcare-associated infections, Cyclic peptides, Acinetobacter baumannii, Pathogenic bacteria, Acinetobacter, Carbapenem, Colistin

KBP-7072, demonstrated potent activity against geographically-diverse strains of A. baumannii including carbapenem-resistant, colistin-resistant and tetracycline-resistant isolates.

Key Points:

KBP-7072, demonstrated potent activity against geographically-diverse strains of A. baumannii including carbapenem-resistant, colistin-resistant and tetracycline-resistant isolates.
Acinetobacter has become a particularly serious public health problem in China and this includes resistance to antibiotics of last resort.
The study evaluated the in vitro activity of KBP-7072 compared to other agents against 531 A. baumannii strains collected in the U.S., Europe, Asia-pacific and Latin America.
KBP Biosciences is actively seeking to identify additional promising therapeutic opportunities and further develop its product portfolio.

ContraFect Announces First Gram-negative Product Candidate CF-370, a Direct Lytic Agent Targeting Pseudomonas aeruginosa

Retrieved on:

Wednesday, December 18, 2019

Bacteria, Gram-negative bacteria, Microorganisms, Infectious diseases, Pathogenic bacteria, Moraxellaceae, Pseudomonadales, Antibiotic-resistant bacteria, Acinetobacter baumannii, Pseudomonas aeruginosa, Pseudomonas, Acinetobacter

The Company expects to present the detailed preclinical data supporting the advancement of CF-370 at an upcoming scientific conference.

Key Points:

The Company expects to present the detailed preclinical data supporting the advancement of CF-370 at an upcoming scientific conference.
We are excited to announce the nomination of CF-370 as our next product candidate.
In these models, CF-370 was well tolerated with no adverse clinical consequences and no deaths among animals infected with P. aeruginosa.
Amurin peptides are a new class of DLAs, which exhibit broad-spectrum activity against a wide range of antibiotic-resistant Gram-negative pathogens, including Pseudomonas aeruginosa (P. aeruginosa), Acinetobacter baumannii, and Enterobacter species.

Entasis Therapeutics to Present at the 28th Annual Credit Suisse Healthcare Conference

Retrieved on:

Tuesday, October 29, 2019

Medical specialties, Medicine, Branches of biology, Pathogenic bacteria, Moraxellaceae, Penicillins, Antibiotic, Drug resistance, Neisseria gonorrhoeae, Acinetobacter, Gram-negative bacteria, β-Lactamase inhibitor

Investors attending the conference who are interested in meeting with Company management should contact their Credit Suisse representatives.

Key Points:

Investors attending the conference who are interested in meeting with Company management should contact their Credit Suisse representatives.
Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria.
Entasis pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targetingAcinetobacter baumanniiinfections), zoliflodacin (targetingNeisseria gonorrhoeae), and ETX0282CPDP (targetingEnterobacteriaceaeinfections).
Entasis is also using its platform to develop a novel class of antibiotics, non--lactam inhibitors of the penicillin-binding proteins (NBPs) (targeting Gram-negative infections).

Entasis Therapeutics to Present at the Wedbush PacGrow Healthcare Conference

Retrieved on:

Tuesday, August 6, 2019

Medical specialties, Medicine, Branches of biology, Gram-negative bacteria, Pathogenic bacteria, Moraxellaceae, Penicillins, Antibiotic, Drug resistance, Neisseria gonorrhoeae, Acinetobacter, β-Lactamase inhibitor

Investors attending the conference who are interested in meeting with Company management should contact their Wedbush representatives.

Key Points:

Investors attending the conference who are interested in meeting with Company management should contact their Wedbush representatives.
Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria.
Entasis pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targetingAcinetobacter baumanniiinfections), zoliflodacin (targetingNeisseria gonorrhoeae), and ETX0282CPDP (targetingEnterobacteriaceaeinfections).
Entasis is also using its platform to develop a novel class of antibiotics, non--lactam inhibitors of the penicillin-binding proteins (NBPs) (targeting Gram-negative infections).